CA2517572A1 - Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia - Google Patents
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia Download PDFInfo
- Publication number
- CA2517572A1 CA2517572A1 CA002517572A CA2517572A CA2517572A1 CA 2517572 A1 CA2517572 A1 CA 2517572A1 CA 002517572 A CA002517572 A CA 002517572A CA 2517572 A CA2517572 A CA 2517572A CA 2517572 A1 CA2517572 A1 CA 2517572A1
- Authority
- CA
- Canada
- Prior art keywords
- alkylene
- nr6r7
- alkyl
- group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/28—Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin
Abstract
The present invention provides substituted azetidinone compounds of formula (I), formulations and processes for preparing the same which can be useful for treating vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols in a subject.
Claims (24)
1. A compound represented by the structural formula (I):
or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein in Formula (I) above:
X, Y and Z can be the same or different and each is independently selected from the group consisting of -CH2-, -CH(alkyl)- and -C(alkyl)2-;
Q1 and Q2 can be the same or different and each is independently selected from the group consisting of H, -(C0-C30 alkylene)-G, -OR6, -OC(O)R6, -OC(O)OR9, -OC(O)NR6R7, and -L-M;
Q3 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C.ident.C-C(O)OR6, -C.ident.C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;
Q4 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6= -CH=CH-C(O)OR6, -C.ident.C-C(O)OR6, -C.ident.C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;
Q5 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C.ident.C-C(O)OR6, -C.ident.C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;
wherein optionally one or more carbon atoms of the -(C0-C30 alkylene)- radical of Q1, Q2, Q3, Q4, and Q5 is independently replaced by -O-, -C(O)-, -CH=CH-, -C.ident.C-, -N(alkyl)-, -N(alkylaryl)- or -NH-;
G is selected from the group consisting of a sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue, oligopeptide residue comprising 2 to 9 amino acids, trialkylammoniumalkyl radical and -S(O)2-OH, wherein optionally the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with -L-M;
L is selected from the group consisting of wherein Me is methyl;
M is selected from the group of moieties consisting of pharmaceutically acceptable salts of the moieties (M1) to (M9) and free acids of the moieties (M1) to (M9);
R2 and R3 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl and aryl;
R6, R7 and R8 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl; and each R9 is independently alkyl, aryl or arylalkyl.
each R10 is independently H or alkyl;
q is 0 or 1;
r is 0 or 1;
m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;
x1 is 1 to 10;
x2 is 1 to 10;
x3 is 1 to 10;
x4 is 1 to 10;
x5 is 1 to 10;
x6 is 1 to 10;
x7 is 1 to 10;
x8 is 1 to 10;
x9 is 1 to l0;
x10 is 1 to 10; and x11 is 1 to 10;
with the proviso that at least one of Q1, Q2, Q3, Q4 and Q5 is -L-M or the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with -L-M.
or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein in Formula (I) above:
X, Y and Z can be the same or different and each is independently selected from the group consisting of -CH2-, -CH(alkyl)- and -C(alkyl)2-;
Q1 and Q2 can be the same or different and each is independently selected from the group consisting of H, -(C0-C30 alkylene)-G, -OR6, -OC(O)R6, -OC(O)OR9, -OC(O)NR6R7, and -L-M;
Q3 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C.ident.C-C(O)OR6, -C.ident.C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;
Q4 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6= -CH=CH-C(O)OR6, -C.ident.C-C(O)OR6, -C.ident.C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;
Q5 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C.ident.C-C(O)OR6, -C.ident.C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;
wherein optionally one or more carbon atoms of the -(C0-C30 alkylene)- radical of Q1, Q2, Q3, Q4, and Q5 is independently replaced by -O-, -C(O)-, -CH=CH-, -C.ident.C-, -N(alkyl)-, -N(alkylaryl)- or -NH-;
G is selected from the group consisting of a sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue, oligopeptide residue comprising 2 to 9 amino acids, trialkylammoniumalkyl radical and -S(O)2-OH, wherein optionally the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with -L-M;
L is selected from the group consisting of wherein Me is methyl;
M is selected from the group of moieties consisting of pharmaceutically acceptable salts of the moieties (M1) to (M9) and free acids of the moieties (M1) to (M9);
R2 and R3 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl and aryl;
R6, R7 and R8 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl; and each R9 is independently alkyl, aryl or arylalkyl.
each R10 is independently H or alkyl;
q is 0 or 1;
r is 0 or 1;
m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;
x1 is 1 to 10;
x2 is 1 to 10;
x3 is 1 to 10;
x4 is 1 to 10;
x5 is 1 to 10;
x6 is 1 to 10;
x7 is 1 to 10;
x8 is 1 to 10;
x9 is 1 to l0;
x10 is 1 to 10; and x11 is 1 to 10;
with the proviso that at least one of Q1, Q2, Q3, Q4 and Q5 is -L-M or the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with -L-M.
2. The compound according to claim 1, wherein m, n and r are each zero, q is 1, p is 2, and Z is -CH2-.
3. The compound according to claim 1, wherein m, n and r are each zero, q is 1, p is 2, and Z is -CH2-, Q1 is -OR6, wherein R6 is hydrogen and Q5 is fluorine.
4. The compound according to claim 1, wherein R2 and R3 are each preferably hydrogen.
5. The compound according to claim 1, wherein Q1 and Q2 are each independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9 and -O(CO)NR6R7.
6. The compound according to claim 1, wherein Q4 is halo or -OR6.
7. The compound according to claim 1, wherein Q1 is -OR6 wherein R6 is H.
8. The compound according to claim 1, wherein Q1, Q2, Q3, Q4 or Q5 is-L-M.
9. The compound according to claim 1, wherein Q1, Q2, Q3, Q4 or Q5 is -(C0-C30 alkylene)-G.
10. The compound according to claim 1, wherein G is selected from the group consisting of:
wherein R, R a and R b can be the same or different and each is independently selected from the group consisting of H, -OH, halo, -NH2, azido, alkoxyalkoxy or -W-R30;
W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R31)-, -NH-C(O)-N(R31)- and -O-C(S)-N(R31)-;
R2a and R6a can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, aryl and arylalkyl;
R3a, R4a, R5a, R7a, R3b and R4b can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, arylalkyl, -C(O)alkyl and -C(O)aryl;
R30 is independently selected from the group consisting of R32-substituted T, R32-substituted-T-alkyl, R32-substituted-alkenyl, R32-substituted-alkyl, R32-substituted-cycloalkyl and R32-substituted-cycloalkylalkyl;
R31 is independently selected from the group consisting of H and alkyl;
T is independently selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;
R32 is 1 to 3 substituents which are each independently selected from the group consisting of H, halo, alkyl, -OH, phenoxy, -CF3, -NO2, alkoxy, methylenedioxy, oxo, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -N(CH3)2, -C(O)-NHalkyl, -C(O)-N(alkyl)2, -C(O)-alkyl, -C(O)-alkoxy and pyrrolidinylcarbonyl; or R32 is a covalent bond and R31, the nitrogen to which it is attached and R32 form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, H-methylpiperazinyl, indolinyl or morpholinyl group.
wherein R, R a and R b can be the same or different and each is independently selected from the group consisting of H, -OH, halo, -NH2, azido, alkoxyalkoxy or -W-R30;
W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R31)-, -NH-C(O)-N(R31)- and -O-C(S)-N(R31)-;
R2a and R6a can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, aryl and arylalkyl;
R3a, R4a, R5a, R7a, R3b and R4b can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, arylalkyl, -C(O)alkyl and -C(O)aryl;
R30 is independently selected from the group consisting of R32-substituted T, R32-substituted-T-alkyl, R32-substituted-alkenyl, R32-substituted-alkyl, R32-substituted-cycloalkyl and R32-substituted-cycloalkylalkyl;
R31 is independently selected from the group consisting of H and alkyl;
T is independently selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;
R32 is 1 to 3 substituents which are each independently selected from the group consisting of H, halo, alkyl, -OH, phenoxy, -CF3, -NO2, alkoxy, methylenedioxy, oxo, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -N(CH3)2, -C(O)-NHalkyl, -C(O)-N(alkyl)2, -C(O)-alkyl, -C(O)-alkoxy and pyrrolidinylcarbonyl; or R32 is a covalent bond and R31, the nitrogen to which it is attached and R32 form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, H-methylpiperazinyl, indolinyl or morpholinyl group.
11. The compound according to claim 10, wherein G is selected from:
wherein Ac is acetyl and Ph is phenyl.
wherein Ac is acetyl and Ph is phenyl.
12. The compound according to claim 1, wherein optionally one or more carbon atoms of the -(C0-C30 alkylene)- radical of Q1, Q2, Q3, Q4 and Q5 is independently replaced by -O -.
13. The compound according to claim 1, wherein L is .
14. The compound according to claim 1, wherein L is .
15. The compound according to claim 1, wherein M is (M1) or pharmaceutically acceptable salts thereof.
16 The compound according to claim 1, wherein M is (M2) or pharmaceutically acceptable salts thereof.
17. The compound according to claim 1, wherein M is (M3) or pharmaceutically acceptable salts thereof.
18. The compound according to claim 1, wherein M is (M4) or pharmaceutically acceptable salts thereof.
19. The compound according to claim 1, wherein M is (M7) or pharmaceutically acceptable salts thereof.
20. The compound according to claim 1, which is selected from the group consisting of
21. A pharmaceutical composition for the treatment or prevention of a vascular condition, diabetes, obesity, stroke, lowering a concentration of a sterol or stanol in plasma of a mammal, preventing demyelination or treating Alzheimer's disease and/or regulating levels of amyloid .beta. peptides in a subject comprising a therapeutically effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising a cholesterol-lowering effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.
23. A method of treating or preventing a vascular condition, diabetes, obesity, stroke, lowering a concentration of a sterol or stanol in plasma of a mammal, preventing demyelination or treating Alzheimer's disease or regulating a level of an amyloid .beta. peptide in a subject comprising the step of administering to a subject in need of such treatment an effective amount of a compound of claim 1.
24. A method of lowering cholesterol level in plasma of a mammal in need of such treatment comprising administering a pharmaceutically effective amount of the compound of claim 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45272503P | 2003-03-07 | 2003-03-07 | |
US60/452,725 | 2003-03-07 | ||
PCT/US2004/006428 WO2004081003A1 (en) | 2003-03-07 | 2004-03-03 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2517572A1 true CA2517572A1 (en) | 2004-09-23 |
CA2517572C CA2517572C (en) | 2011-12-13 |
Family
ID=32990674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2517572A Expired - Fee Related CA2517572C (en) | 2003-03-07 | 2004-03-03 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
Country Status (11)
Country | Link |
---|---|
US (3) | US7208486B2 (en) |
EP (1) | EP1601669B1 (en) |
JP (2) | JP4589919B2 (en) |
CN (1) | CN1756756A (en) |
AT (1) | ATE418551T1 (en) |
CA (1) | CA2517572C (en) |
DE (1) | DE602004018617D1 (en) |
ES (1) | ES2318274T3 (en) |
HK (1) | HK1085728A1 (en) |
MX (1) | MXPA05009501A (en) |
WO (1) | WO2004081003A1 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7176194B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
CN1756755A (en) * | 2003-03-07 | 2006-04-05 | 先灵公司 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
JP5137228B2 (en) * | 2003-03-07 | 2013-02-06 | メルク・シャープ・アンド・ドーム・コーポレーション | Substituted azetidinone compounds, substituted azetidinone formulations and their use for the treatment of hypercholesterolemia |
DE602004018617D1 (en) | 2003-03-07 | 2009-02-05 | Schering Corp | SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF HYPERCHOLESTEROLMIA |
AU2004308332B2 (en) * | 2003-12-23 | 2008-04-10 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
WO2007001975A1 (en) * | 2005-06-20 | 2007-01-04 | Schering Corporation | Piperidine derivatives useful as histamine h3 antagonists |
WO2007016643A2 (en) * | 2005-08-01 | 2007-02-08 | Mount Sinai School Of Medicine Of New York University | A method for extending longevity using npc1l1 antagonists |
CA2616058A1 (en) * | 2005-09-08 | 2007-03-15 | Vinod Kumar Kansal | Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe |
US20070275075A1 (en) * | 2006-03-06 | 2007-11-29 | Ilan Zalit | Ezetimibe compositions |
JP2010502702A (en) * | 2006-09-05 | 2010-01-28 | シェーリング コーポレイション | Pharmaceutical composition for use in lipid management and therapeutic treatment of atherosclerosis and fatty liver |
US20080139527A1 (en) * | 2006-12-08 | 2008-06-12 | Reddy Kota J | Methods for treatment of heart disease |
WO2009032264A1 (en) * | 2007-08-30 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Processes for preparing intermediates of ezetimibe by microbial reduction |
CA2716835A1 (en) * | 2008-02-27 | 2009-09-03 | Amcol International Corporation | Methods of treating cardiovascular disorders associated with atherosclerosis |
US8252834B2 (en) | 2008-03-12 | 2012-08-28 | The Regents Of The University Of Michigan | Dendrimer conjugates |
WO2010039861A2 (en) | 2008-09-30 | 2010-04-08 | The Regents Of The University Of Michigan | Dendrimer conjugates |
WO2010054321A2 (en) | 2008-11-07 | 2010-05-14 | The Regents Of The University Of Michigan | Methods of treating autoimmune disorders and/or inflammatory disorders |
WO2010100255A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
US20120177593A1 (en) * | 2009-07-20 | 2012-07-12 | The Regents Of The University Of Michigan | Synthesis of dendrimer conjugates |
CA2777682C (en) | 2009-10-13 | 2015-02-24 | The Regents Of The University Of Michigan | Dendrimer compositions and methods of synthesis |
WO2011059586A2 (en) | 2009-10-30 | 2011-05-19 | The Regents Of The University Of Michigan | Multifunctional small molecules |
ES2552657T3 (en) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibitors of the recycling of bile acids and satiogens for the treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
BR112014010223B8 (en) | 2011-10-28 | 2021-02-23 | Lumena Pharmaceuticals Llc | use of a composition comprising bile acid recycling inhibitors and pediatric dosage form |
CN104023718B (en) | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | For treating the bile acid recycling inhibitors of high cholemia and cholestatic liver disease |
US9402911B2 (en) | 2011-12-08 | 2016-08-02 | The Regents Of The University Of Michigan | Multifunctional small molecules |
KR20230152818A (en) | 2013-03-15 | 2023-11-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
RU2015139732A (en) | 2013-03-15 | 2017-04-24 | ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи | Bile Acid Recirculation Inhibitors for the Treatment of Barrett's Esophagus and Gastroesophageal Reflux Disease |
AU2020221239A1 (en) | 2019-02-12 | 2021-09-16 | Mirum Pharmaceuticals, Inc. | Methods for treating cholestasis |
Family Cites Families (312)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3108097A (en) | 1963-10-22 | Ehnojs | ||
US2809194A (en) | 1957-10-08 | Thiadiazine type natriuretic agents | ||
FR1103113A (en) | 1954-04-15 | 1955-10-31 | Trimethylol alkanes and their preparation process | |
FR1217929A (en) | 1958-03-03 | 1960-05-06 | Ciba Geigy | Process for the preparation of 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide and its salts |
BE578515A (en) | 1958-05-07 | |||
DE1302648B (en) | 1960-09-27 | |||
NL127065C (en) | 1964-04-22 | |||
NL137318C (en) | 1964-06-09 | |||
GB1415295A (en) | 1971-10-14 | 1975-11-26 | Orchimed Sa | Substituted phenoxy-alkyl-carboxylic acids and derivatives thereof |
FI52570C (en) | 1969-04-16 | 1977-10-10 | Sumitomo Chemical Co | Process for producing the cholesterol or lipoid content of the blood using phenoxyaliphatic carboxylic acid compounds and ester compounds. |
US3692895A (en) | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
DE2046823A1 (en) | 1970-09-23 | 1972-03-30 | Farbwerke Hoechst AG vormals Meister Lucius & Brüning, 6000 Frankfurt | New azetidinones (2) and processes for their preparation |
DE2230383C3 (en) | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarboxylic acid derivatives and processes for making the same |
US4148923A (en) | 1972-05-31 | 1979-04-10 | Synthelabo | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity |
US3948973A (en) | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
US4626549A (en) | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
DE2521113A1 (en) | 1974-05-15 | 1976-03-18 | Maggioni & C Spa | CYCLOALIPHATIC DERIVATIVES OF 3.3-DIPHENYLPROPYLAMINE |
US4179515A (en) | 1975-02-12 | 1979-12-18 | Orchimed S. A. | Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition |
JPS5195049A (en) | 1975-02-12 | 1976-08-20 | * **********so*****no***tsu*****************************************ni*no | |
US4235896A (en) | 1975-02-12 | 1980-11-25 | Orchimed S.A. | Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same |
US4075000A (en) | 1975-05-27 | 1978-02-21 | Eli Lilly And Company | Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones |
US4576753A (en) | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
US4304718A (en) | 1975-10-06 | 1981-12-08 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4472309A (en) | 1975-10-06 | 1984-09-18 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4166907A (en) | 1976-11-01 | 1979-09-04 | E. R. Squibb & Sons, Inc. | 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity |
US4144232A (en) | 1976-12-23 | 1979-03-13 | Eli Lilly And Company | Substituted azetidin-2-one antibiotics |
FR2403078A1 (en) | 1977-09-19 | 1979-04-13 | Lafon Labor | NEW PROCESS FOR THE PREPARATION OF PHARMACEUTICAL, COSMETIC OR DIAGNOSIS FORMS |
IT1157365B (en) | 1977-10-24 | 1987-02-11 | Sandoz Ag | MEDICATIONS TO TREAT OBESITY OR REDUCE BODY WEIGHT |
FR2408577A1 (en) | 1977-11-14 | 1979-06-08 | Devinter Sa | NEW PROCESS FOR THE SYNTHESIS OF ISOBUTYRIC PARA CHLOROBENZOYL PHENOXY ESTERS |
NZ191762A (en) | 1978-10-19 | 1982-09-14 | Merck & Co Inc | Hypocholesteremic composition containing cholesterol synthesis inhibitor and anion exchange resin |
US4250191A (en) | 1978-11-30 | 1981-02-10 | Edwards K David | Preventing renal failure |
US4375475A (en) | 1979-08-17 | 1983-03-01 | Merck & Co., Inc. | Substituted pyranone inhibitors of cholesterol synthesis |
US4260743A (en) | 1979-12-31 | 1981-04-07 | Gist-Brocades N.V. | Preparation of β-lactams and intermediates therefor |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
ES8101585A1 (en) | 1980-02-15 | 1980-12-16 | Especialidades Farmaco Terape | Glyceryl 2-para-chloro:phenoxy-isobutyrate-1,3-di:nicotinate - hypolipaemic and hypocholesterolaemic used to treat atherosclerosis, hyperlipoproteinaemia and high tri:glyceride plasma levels |
DE3107100A1 (en) | 1981-02-20 | 1982-09-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | AZAPROSTACYCLINE, METHOD FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE |
US4500456A (en) | 1981-03-09 | 1985-02-19 | Eli Lilly And Company | Preparation of 4-fluoroazetidinones using FClO3 |
US4784734A (en) | 1981-04-10 | 1988-11-15 | Otsuka Kagaku Yakuhin Kabushiki Kaisha | Azetidinone derivatives and process for the preparation of the same |
US4602005A (en) | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis |
US4602003A (en) | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia |
US4534786A (en) | 1982-06-23 | 1985-08-13 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4443372A (en) | 1982-06-23 | 1984-04-17 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4595532A (en) | 1983-02-02 | 1986-06-17 | University Of Notre Dame Du Lac | N-(substituted-methyl)-azetidin-2-ones |
CA1256650A (en) | 1983-03-25 | 1989-06-27 | Toshinari Tamura | Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds |
US4614614A (en) | 1983-03-28 | 1986-09-30 | Ciba-Geigy Corporation | Process for the manufacture of optically active azetidinones |
US4675399A (en) | 1983-03-28 | 1987-06-23 | Notre Dame University | Cyclization process for β-lactams |
WO1985004876A1 (en) | 1984-04-24 | 1985-11-07 | Takeda Chemical Industries, Ltd. | 2-azetidinone derivatives and process for their preparation |
US4576749A (en) | 1983-10-03 | 1986-03-18 | E. R. Squibb & Sons, Inc. | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones |
US5229510A (en) | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | β-lactams useful in determining the amount of elastase in a clinical sample |
US4680391A (en) | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US5229381A (en) | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US4654362A (en) | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
FR2561916B1 (en) | 1984-03-30 | 1987-12-11 | Lafon Labor | GALENIC FORM FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING IT BY LYOPHILIZATION OF AN OIL-TO-WATER EMISSION |
US4567748A (en) * | 1984-07-19 | 1986-02-04 | Klass Carl S | On-line linear tonometer |
US4633017A (en) | 1984-08-03 | 1986-12-30 | E. R. Squibb & Sons, Inc. | N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4581170A (en) | 1984-08-03 | 1986-04-08 | E. R. Squibb & Sons, Inc. | N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4576748A (en) | 1984-09-17 | 1986-03-18 | Merck & Co., Inc. | 3-Hydroxy-3-aminoethyl β-lactams |
US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
US4620867A (en) | 1984-09-28 | 1986-11-04 | Chevron Research Company | 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides |
AR240698A1 (en) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts |
US4642903A (en) | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
US4680289A (en) | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
JPH0679559B2 (en) | 1985-06-06 | 1994-10-12 | 三共株式会社 | Process for producing optically active azetidinone derivative |
DE3787815T2 (en) | 1986-02-19 | 1994-03-24 | Sanraku Inc | Azetidinone derivatives. |
GB8607312D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
FR2598146B1 (en) | 1986-04-30 | 1989-01-20 | Rech Ind | NEW PROCESS FOR THE PREPARATION OF FIBRATES. |
DE3621861A1 (en) | 1986-06-30 | 1988-01-14 | Laszlo Dr Med Ilg | USE OF ARYLOXYCARBONIC ACID DERIVATIVES AGAINST DERMATOLOGICAL DISEASES |
JPS6317859A (en) | 1986-07-11 | 1988-01-25 | Sagami Chem Res Center | Fluoroazetidinone derivative |
FR2602423B1 (en) | 1986-08-08 | 1989-05-05 | Ethypharm Sa | PROCESS FOR THE PREPARATION OF A FENOFIBRATE-BASED MEDICINAL PRODUCT, OBTAINED BY THIS PROCESS |
US4814354A (en) | 1986-09-26 | 1989-03-21 | Warner-Lambert Company | Lipid regulating agents |
PT85850B (en) | 1986-10-03 | 1990-01-12 | Lilly Co Eli | Process for preparing 7-((meta-substituted) phenylglycine)-1-carba-1-dethiacephalosporins |
US4803266A (en) | 1986-10-17 | 1989-02-07 | Taisho Pharmaceutical Co., Ltd. | 3-Oxoalkylidene-2-azetidinone derivatives |
ZA879415B (en) | 1986-12-15 | 1989-08-30 | Lilly Co Eli | Antibiotic a10255 complex and factors,microorganisms,process and production therefor |
IE60394B1 (en) | 1986-12-15 | 1994-07-13 | Lilly Co Eli | Antibiotic A10255 complex and factors, process, microorganisms for its production |
US5229362A (en) | 1986-12-15 | 1993-07-20 | Eli Lilly And Company | Antibiotic A10255 complex and factors, and process and production therefor |
JPS63156788A (en) | 1986-12-22 | 1988-06-29 | Sanraku Inc | Optically active azetidinones |
US5110730A (en) | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
US4879301A (en) | 1987-04-28 | 1989-11-07 | Hoei Pharmaceutical Co., Ltd. | Antiallergic and antiinflammatory benzothiazolinone derivatives |
US5106833A (en) | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
DD273634A5 (en) | 1987-10-06 | 1989-11-22 | ����@�����@�����@����k�� | PROCESS FOR PREPARING A CRYSTALLINE MONOHYDRATE OF A 1-CARBACEPHALOSPORIN |
US5091525A (en) | 1987-10-07 | 1992-02-25 | Eli Lilly And Company | Monohydrate and DMF solvates of a new carbacephem antibiotic |
US4834846A (en) | 1987-12-07 | 1989-05-30 | Merck & Co., Inc. | Process for deblocking N-substituted β-lactams |
US5385885A (en) * | 1988-01-15 | 1995-01-31 | Gasic; Gregory P. | Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide |
FR2627696B1 (en) | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | NEW GALENIC FORM OF FENOFIBRATE |
DE3807895A1 (en) | 1988-03-10 | 1989-09-21 | Knoll Ag | PRODUCTS CONTAINING A CALCIUM ANTAGONIST AND A LIPID DOWNER |
EP0333268A1 (en) | 1988-03-18 | 1989-09-20 | Merck & Co. Inc. | Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone |
NZ228600A (en) | 1988-04-11 | 1992-02-25 | Merck & Co Inc | 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives |
GB8813012D0 (en) | 1988-06-02 | 1988-07-06 | Norsk Hydro As | Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals |
FR2634376B1 (en) * | 1988-07-21 | 1992-04-17 | Farmalyoc | NOVEL SOLID AND POROUS UNIT FORM COMPRISING MICROPARTICLES AND / OR NANOPARTICLES, AS WELL AS ITS PREPARATION |
US4952689A (en) | 1988-10-20 | 1990-08-28 | Taisho Pharmaceutical Co., Ltd. | 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation |
CA2002596A1 (en) | 1988-11-14 | 1990-05-14 | Thomas M. Eckrich | Hydrates of b-lactam antibiotic |
CA1340977C (en) * | 1988-11-15 | 2000-04-25 | Monty Krieger | Scavenger receptor protein and antibody thereto |
US5073374A (en) | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US5112616A (en) | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
US4876365A (en) | 1988-12-05 | 1989-10-24 | Schering Corporation | Intermediate compounds for preparing penems and carbapenems |
US5260305A (en) | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
FR2640621B1 (en) | 1988-12-19 | 1992-10-30 | Centre Nat Rech Scient | N-ARYL-AZETIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ELASTASE INHIBITORS |
US4990535A (en) | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
CA2016467A1 (en) | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
JPH03108490A (en) | 1989-06-30 | 1991-05-08 | Shionogi & Co Ltd | Phospholipase a2 inhibitor |
US5021461A (en) | 1989-07-26 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Method of treating diabetes mellitus with bisphenol derivatives |
US4983597A (en) | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
US5219574A (en) | 1989-09-15 | 1993-06-15 | Cima Labs. Inc. | Magnesium carbonate and oil tableting aid and flavoring additive |
US5223264A (en) | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5188825A (en) | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
CA2039763A1 (en) | 1990-04-30 | 1991-10-31 | Henry Y. Pan | Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination |
CA2040865C (en) | 1990-05-15 | 2002-07-23 | James L. Bergey | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
US5298497A (en) | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
CA2042526A1 (en) | 1990-06-11 | 1991-12-12 | Adeoye Y. Olukotun | Method for preventing a second heart attack employing an hmg coa reductase inhibitor |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US5120729A (en) | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
JP2901196B2 (en) | 1990-06-21 | 1999-06-07 | メルシャン株式会社 | Method for producing (3S, 4S) -3-[(1R) -1-hydroxyethyl] -2-azetidinone derivative |
CA2048395A1 (en) | 1990-08-23 | 1992-02-24 | Henry Y. Pan | Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin |
US5120713A (en) | 1990-09-10 | 1992-06-09 | Applied Research Systems Ars Holding N.V. | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
US5075313A (en) | 1990-09-13 | 1991-12-24 | Eli Lilly And Company | 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof |
IL99658A0 (en) | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
US5190970A (en) | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
US5130333A (en) | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
CA2052014A1 (en) | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
JP2640986B2 (en) | 1990-11-08 | 1997-08-13 | 高砂香料工業株式会社 | Process for producing (1'R, 3S) -3- (1'-hydroxyethyl) -azetidin-2-one or a derivative thereof |
IL100091A (en) * | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
AU642066B2 (en) | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
JPH04266869A (en) | 1991-02-20 | 1992-09-22 | Dai Ichi Seiyaku Co Ltd | Fluorine-containing azetidinone derivative |
US5157025A (en) | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
JPH04356195A (en) | 1991-05-30 | 1992-12-09 | Kyowa Hakko Kogyo Co Ltd | Production of azetidinone derivative |
US5348953A (en) | 1991-06-25 | 1994-09-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
US5688785A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5688787A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
ES2107548T3 (en) | 1991-07-23 | 1997-12-01 | Schering Corp | SUBSTITUTED BETA-LACTAMA COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS AND PROCEDURES FOR THEIR PREPARATION. |
US5561227A (en) | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
JPH0558993A (en) | 1991-08-30 | 1993-03-09 | Yoshitomi Pharmaceut Ind Ltd | Azetidinone compound and its production |
JP2620437B2 (en) | 1991-09-27 | 1997-06-11 | 宇部興産株式会社 | Process for producing ω-hydroxy- (ω-3) -ketonitrile and ω-hydroxy fatty acid |
US5162117A (en) | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
JPH05239020A (en) | 1991-12-27 | 1993-09-17 | Takeda Chem Ind Ltd | Production of 3-(r)-1-(substituted-oxycarbonyloxy) ethyl)-4-substituted-2-azetidinone |
JP3852621B2 (en) | 1992-01-21 | 2006-12-06 | あすか製薬株式会社 | Vascular endothelial cell function improving agent |
DE4203932A1 (en) | 1992-02-11 | 1993-08-12 | Deutsche Aerospace | SEND / RECEIVE MODULE |
US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
US5278176A (en) | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
WO1994010143A1 (en) | 1992-10-27 | 1994-05-11 | Merck & Co., Inc. | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
US5631363A (en) | 1992-11-13 | 1997-05-20 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
AU660852B2 (en) * | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5358852A (en) | 1992-12-21 | 1994-10-25 | Eastman Kodak Company | Use of calcium in immunoassay for measurement of C-reactive protein |
LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
US5563264A (en) | 1993-02-10 | 1996-10-08 | Shionogi & Co., Ltd. | Preparation of βlactam compounds |
US5503846A (en) * | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
US5412092A (en) | 1993-04-23 | 1995-05-02 | Bristol-Myers Squibb Company | N-substituted 2-azetidinones |
US5703188A (en) | 1993-06-02 | 1997-12-30 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
US5550229A (en) | 1993-06-23 | 1996-08-27 | Tanabe Seiyaku Co., Ltd. | Alkylation process for preparing azetidinone compound and starting compound therefor |
SK3796A3 (en) * | 1993-07-09 | 1997-02-05 | Schering Corp | Process for the synthesis of azetidinones |
ATE208615T1 (en) * | 1993-07-09 | 2001-11-15 | Scherer Corp R P | METHOD FOR PRODUCING FREEZE-DRIED MEDICINAL DOSAGE FORMS |
US5851553A (en) | 1993-09-10 | 1998-12-22 | Fuisz Technologies, Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5895664A (en) | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5976570A (en) | 1993-12-21 | 1999-11-02 | Applied Analytical Industries, Inc. | Method for preparing low dose pharmaceutical products |
US6369103B1 (en) | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
US5595761A (en) | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
US5576014A (en) | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
GB9401892D0 (en) * | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
US5635210A (en) * | 1994-02-03 | 1997-06-03 | The Board Of Regents Of The University Of Oklahoma | Method of making a rapidly dissolving tablet |
US5627176A (en) | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
GB9406074D0 (en) | 1994-03-26 | 1994-05-18 | Glaxo Spa | Chemical process |
US5554746A (en) | 1994-05-16 | 1996-09-10 | Isis Pharmaceuticals, Inc. | Lactam nucleic acids |
US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5567439A (en) | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
MX9702175A (en) | 1994-09-20 | 1997-06-28 | Pfizer | Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor. |
GB9421836D0 (en) | 1994-10-28 | 1994-12-14 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms of hydrophobic substances |
GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
DZ1958A1 (en) | 1994-12-22 | 2002-02-17 | Smithkline Beecham Plc | Compounds inhibitors of the enzyme l-lpa pharmaceutical compositions composing them and methods for their preparation. |
US5902726A (en) | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
US5545628A (en) | 1995-01-10 | 1996-08-13 | Galephar P.R. Inc. | Pharmaceutical composition containing fenofibrate |
FR2730231B1 (en) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | COMBINATION OF FENOFIBRATE AND VITAMIN E, USE IN THERAPEUTICS |
US5639475A (en) * | 1995-02-03 | 1997-06-17 | Eurand America, Incorporated | Effervescent microcapsules |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
US5998441A (en) | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
US5639739A (en) * | 1995-03-24 | 1997-06-17 | The Dupont Merck Pharmaceutical Company | Imidazole containing aminoboronic acids |
US5759865A (en) * | 1995-05-03 | 1998-06-02 | Eli Lilly And Company | Combinatorial process for synthesizing azetidinone analogs |
DE19518988A1 (en) | 1995-05-29 | 1996-12-05 | Basf Ag | Use of aryl substituted cyclobutylalkylamines to treat obesity |
JP3144624B2 (en) * | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N-benzyldioxothiazolidylbenzamide derivative and method for producing the same |
US5612378A (en) * | 1995-06-06 | 1997-03-18 | 3-Dimensional Pharmaceuticals, Inc. | Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors |
US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
RU2158607C2 (en) | 1995-07-03 | 2000-11-10 | Санкио Компани Лимитед | Arteriosclerosis and xanthoma treatment |
FR2737121B1 (en) | 1995-07-27 | 1997-10-03 | Cl Pharma | NEW GALENIC FORMULATIONS OF FENOFIBRATE AND THEIR APPLICATIONS |
US5698527A (en) | 1995-08-08 | 1997-12-16 | Merck & Co., Inc. | Steroidal glycosides as antihyperlipidemic agents |
FR2738817B1 (en) * | 1995-09-14 | 1997-10-17 | Adir | NOVEL SUBSTITUTED ALKANOIC 2,2-DIMETHYL-OMEGA-PHENOXY ACIDS AND ESTERS, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5618707A (en) * | 1996-01-04 | 1997-04-08 | Schering Corporation | Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof |
US5808056A (en) | 1995-10-31 | 1998-09-15 | Merck & Co., Inc. | Process for preparing substituted azetidinones |
AU7472896A (en) * | 1995-11-02 | 1997-05-22 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon |
EP0861073B1 (en) * | 1995-11-14 | 2004-07-28 | Abbott GmbH & Co. KG | Stabilized thyroid hormone preparations and methods of making same |
US5925333A (en) | 1995-11-15 | 1999-07-20 | Massachusetts Institute Of Technology | Methods for modulation of lipid uptake |
JPH09143156A (en) | 1995-11-17 | 1997-06-03 | Tanabe Seiyaku Co Ltd | Production of acetoxyazetidinone derivative and its synthetic intermediate |
US5807578A (en) | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
US5807577A (en) | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
US6080767A (en) * | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
US5847008A (en) | 1996-02-02 | 1998-12-08 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
DE19608750A1 (en) | 1996-03-06 | 1997-09-11 | Durachemie Gmbh & Co Kg | Process for the production of fenofibrate preparations |
GB9606805D0 (en) * | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
US5858409A (en) * | 1996-04-17 | 1999-01-12 | Fmc Corporation | Hydrolyzed cellulose granulations for pharmaceuticals |
US5843984A (en) | 1996-05-09 | 1998-12-01 | Eli Lilly And Company | Sulfated benzothiophene derivatives, methods of use and formulations containing same |
US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
US5739321A (en) * | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
US6245743B1 (en) * | 1996-06-05 | 2001-06-12 | Cor Therapeutics, Inc. | Inhibitors of factor Xa |
JP3938942B2 (en) * | 1996-06-12 | 2007-06-27 | 協和醗酵工業株式会社 | Lipid metabolism improver |
US5965553A (en) | 1996-06-20 | 1999-10-12 | Pfizer Inc. | Squalene synthetase inhibitors |
US6139873A (en) | 1996-07-10 | 2000-10-31 | Cedars-Sinai Medical Center | Combined pharmaceutical estrogen-androgen-progestin |
US5883109A (en) * | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
US5952003A (en) | 1996-08-01 | 1999-09-14 | Novartis Corporation | Terazosin capsules |
US6057342A (en) * | 1996-08-16 | 2000-05-02 | Dupont Pharmaceutical Co. | Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof |
US6251852B1 (en) * | 1996-09-18 | 2001-06-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US6235706B1 (en) * | 1996-09-18 | 2001-05-22 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US5959123A (en) | 1996-09-23 | 1999-09-28 | Synphar Laboratories, Inc. | 3,4-Disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators |
US6262047B1 (en) | 1996-10-11 | 2001-07-17 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
WO1998023279A1 (en) | 1996-11-27 | 1998-06-04 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND |
US6090839A (en) | 1996-12-23 | 2000-07-18 | Merck & Co., Inc. | Antidiabetic agents |
FR2758459B1 (en) * | 1997-01-17 | 1999-05-07 | Pharma Pass | FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME |
US6066653A (en) * | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
ES2239801T3 (en) * | 1997-04-02 | 2005-10-01 | The Brigham And Women's Hospital, Inc. | USE OF AN AGENT TO DECREASE THE RISK OF CARDIOVASCULAR DISEASE. |
JP2001523245A (en) | 1997-04-24 | 2001-11-20 | メルク シヤープ エンド ドーム リミテツド | Use of NK-1 receptor antagonists and SSRIs to treat obesity |
NZ528906A (en) | 1997-05-14 | 2005-06-24 | Atherogenics Inc | Compounds and methods for the inhibition of the expression of VCAM-1 |
US6117429A (en) | 1997-08-11 | 2000-09-12 | Weider Nutrition International, Inc | Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors |
US5886191A (en) * | 1997-08-18 | 1999-03-23 | Dupont Pharmaceuticals Company | Amidinoindoles, amidinoazoles, and analogs thereof |
US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
US6143885A (en) | 1997-08-27 | 2000-11-07 | Merck & Co., Inc. | Preparation of beta-methyl carbapenem intermediates |
AU9309898A (en) * | 1997-09-09 | 1999-03-29 | Du Pont Pharmaceuticals Company | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa |
GB2329334A (en) | 1997-09-18 | 1999-03-24 | Reckitt & Colmann Prod Ltd | Cholesterol-lowering agents |
CA2214895C (en) | 1997-09-19 | 1999-04-20 | Bernard Charles Sherman | Improved pharmaceutical composition comprising fenofibrate |
IE970731A1 (en) | 1997-10-07 | 2000-10-04 | Fuisz Internat Ltd | Product and method for the treatment of hyperlipidemia |
US6147109A (en) | 1997-10-14 | 2000-11-14 | The General Hospital Corporation | Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors |
US6005102A (en) | 1997-10-15 | 1999-12-21 | American Home Products Corporation | Aryloxy-alkyl-dialkylamines |
US6067342A (en) * | 1997-10-30 | 2000-05-23 | Analogic Corporation | Digital filmless X-ray projection imaging system and method |
US20030153541A1 (en) | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
JP4738592B2 (en) | 1997-10-31 | 2011-08-03 | アーチ・デヴェロップメント・コーポレイション | Methods and compositions for modulating 5α-reductase activity |
US6027747A (en) * | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
US5985936A (en) | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
US6008237A (en) | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
US6133001A (en) | 1998-02-23 | 2000-10-17 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone |
US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
US6180625B1 (en) * | 1998-03-24 | 2001-01-30 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
AU3110999A (en) * | 1998-03-27 | 1999-10-18 | Du Pont Pharmaceuticals Company | Disubstituted pyrazolines and triazolines as factor xa inhibitors |
JP2004503462A (en) | 1998-04-29 | 2004-02-05 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | N-substituted aminotetralins as ligands for neuropeptide YY5 receptor useful in treating obesity and other disorders |
US6262042B1 (en) | 1998-05-29 | 2001-07-17 | Research Triangle Institute | 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
FR2779347A1 (en) | 1998-06-05 | 1999-12-03 | Arlette Guerry | Micronization of medicaments to improve homogeneity and bioavailability of active compound |
US6099865A (en) | 1998-07-08 | 2000-08-08 | Fmc Corporation | Croscarmellose taste masking |
ES2255294T3 (en) | 1998-08-07 | 2006-06-16 | Chiron Corporation | ISOXAZOL DERIVATIVES REPLACED AS MODULATORS OF THE STROGEN RECEPTOR. |
US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US5919672A (en) * | 1998-10-02 | 1999-07-06 | Schering Corporation | Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone |
US6248781B1 (en) * | 1998-10-21 | 2001-06-19 | Novo Nordisk A/S | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) |
CA2253769C (en) | 1998-11-10 | 2000-09-26 | Bernard Charles Sherman | Pharmaceutical compositions comprising fenofibrate |
US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
US6277584B1 (en) | 1998-12-16 | 2001-08-21 | Dade Behring Inc. | Method for calibrating a chemical analyzer with improved accuracy at low signal levels |
US6180138B1 (en) * | 1999-01-29 | 2001-01-30 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
EP1036563A1 (en) | 1999-03-08 | 2000-09-20 | MERCK & CO. INC. | Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof |
DE19916108C1 (en) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | 1,4-Benzothiazepine-1,1-dioxide derivatives substituted with sugar residues, process for their preparation and their use |
CA2270306C (en) | 1999-04-27 | 2000-09-26 | Bernard Charles Sherman | Pharmaceutical compositions comprising co-micronized fenofibrate |
US6033656A (en) * | 1999-05-04 | 2000-03-07 | Sumitomo Chemical Company, Limited | Method of preventing or alleviating mammalian obesity |
US6207699B1 (en) * | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
US6174665B1 (en) * | 1999-09-10 | 2001-01-16 | Biex, Inc. | Hormone replacement therapy monitoring |
DE60019741T2 (en) * | 1999-12-08 | 2006-03-02 | Pharmacia Corp., Chicago | NANOPARTICLE COMPOSITIONS CONTAINING EPLERENONE |
WO2001056579A1 (en) | 2000-02-04 | 2001-08-09 | Esperion Therapeutics Inc. | Methods for treating alzheimer's disease |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
US20020013334A1 (en) | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
US20020132855A1 (en) | 2000-08-03 | 2002-09-19 | Nelson Edward B. | Use of acetaminophen to prevent and treat arteriosclerosis |
DE10042447A1 (en) * | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Vertebrate intestinal protein that absorbs cholesterol and use of this protein to identify inhibitors of intestinal cholesterol transport |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
HUP0401073A2 (en) | 2000-12-21 | 2004-09-28 | Aventis Pharma Deutschland Gmbh. | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
SK7822003A3 (en) * | 2000-12-21 | 2003-12-02 | Aventis Pharma Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
CZ20032031A3 (en) | 2001-01-26 | 2003-12-17 | Schering Corporation | Pharmaceutical preparation |
US20030053981A1 (en) * | 2001-01-26 | 2003-03-20 | Schering Corporation | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
NZ542090A (en) | 2001-01-26 | 2006-09-29 | Schering Corp | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
CA2434430A1 (en) | 2001-01-26 | 2002-08-01 | Harry R. Davis | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
TW200840563A (en) | 2001-01-26 | 2008-10-16 | Schering Corp | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications |
RS51449B (en) | 2001-01-26 | 2011-04-30 | Schering Corporation | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
US7348334B2 (en) * | 2001-04-09 | 2008-03-25 | Dr. Reddy's Laboratories Limited | Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
US20030013699A1 (en) * | 2001-05-25 | 2003-01-16 | Davis Harry R. | Methods for treating alzheimer's disease and/or regulating levels of amyloid beta peptides in a subject |
US20030119808A1 (en) | 2001-09-21 | 2003-06-26 | Schering Corporation | Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects |
US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
DE60216300T2 (en) | 2001-09-21 | 2007-06-28 | Schering Corp. | TREATMENT OF XANTHOM BY AZETIDINONE DERIVATIVES AS AN INHIBITOR OF STEROL ABSORPTION |
CN1556700A (en) | 2001-09-21 | 2004-12-22 | ���鹫˾ | Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) |
US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
JP2003099234A (en) * | 2001-09-25 | 2003-04-04 | Brother Ind Ltd | Electronic equipment and its service support system |
US7176194B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
CN1756755A (en) * | 2003-03-07 | 2006-04-05 | 先灵公司 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
JP5137228B2 (en) * | 2003-03-07 | 2013-02-06 | メルク・シャープ・アンド・ドーム・コーポレーション | Substituted azetidinone compounds, substituted azetidinone formulations and their use for the treatment of hypercholesterolemia |
DE602004018617D1 (en) | 2003-03-07 | 2009-02-05 | Schering Corp | SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF HYPERCHOLESTEROLMIA |
US7459442B2 (en) * | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
JP4356495B2 (en) | 2004-03-31 | 2009-11-04 | サクサ株式会社 | Data processing apparatus and program |
US20090005321A1 (en) * | 2005-02-09 | 2009-01-01 | Microbia, Inc. | Phenylazetidinone Derivatives |
EP1872138A1 (en) * | 2005-04-11 | 2008-01-02 | AstraZeneca AB | A method and a kit for diagnosing type 2 diabetes, metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes. |
EP1868653A2 (en) | 2005-04-12 | 2007-12-26 | PSivida Inc. | Hmgcoa reductase inhibitor codrugs and uses thereof |
-
2004
- 2004-03-03 DE DE602004018617T patent/DE602004018617D1/en not_active Expired - Lifetime
- 2004-03-03 CA CA2517572A patent/CA2517572C/en not_active Expired - Fee Related
- 2004-03-03 MX MXPA05009501A patent/MXPA05009501A/en active IP Right Grant
- 2004-03-03 AT AT04716913T patent/ATE418551T1/en not_active IP Right Cessation
- 2004-03-03 US US10/792,346 patent/US7208486B2/en active Active
- 2004-03-03 ES ES04716913T patent/ES2318274T3/en not_active Expired - Lifetime
- 2004-03-03 EP EP04716913A patent/EP1601669B1/en not_active Expired - Lifetime
- 2004-03-03 CN CNA2004800060488A patent/CN1756756A/en active Pending
- 2004-03-03 WO PCT/US2004/006428 patent/WO2004081003A1/en active Application Filing
- 2004-03-03 JP JP2006509018A patent/JP4589919B2/en not_active Expired - Fee Related
-
2006
- 2006-05-16 HK HK06105698.8A patent/HK1085728A1/en not_active IP Right Cessation
-
2007
- 2007-02-20 US US11/708,449 patent/US7378518B2/en not_active Expired - Lifetime
-
2008
- 2008-04-24 US US12/108,729 patent/US7732413B2/en active Active
-
2010
- 2010-08-16 JP JP2010181957A patent/JP2010254719A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US7208486B2 (en) | 2007-04-24 |
CA2517572C (en) | 2011-12-13 |
US7732413B2 (en) | 2010-06-08 |
JP2010254719A (en) | 2010-11-11 |
HK1085728A1 (en) | 2006-09-01 |
DE602004018617D1 (en) | 2009-02-05 |
EP1601669B1 (en) | 2008-12-24 |
CN1756756A (en) | 2006-04-05 |
US7378518B2 (en) | 2008-05-27 |
US20070155676A1 (en) | 2007-07-05 |
US20040180861A1 (en) | 2004-09-16 |
MXPA05009501A (en) | 2005-10-18 |
JP2007524597A (en) | 2007-08-30 |
US20080200446A1 (en) | 2008-08-21 |
ATE418551T1 (en) | 2009-01-15 |
ES2318274T3 (en) | 2009-05-01 |
EP1601669A1 (en) | 2005-12-07 |
JP4589919B2 (en) | 2010-12-01 |
WO2004081003A1 (en) | 2004-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2517572A1 (en) | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | |
CA2517571A1 (en) | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | |
CA2517573A1 (en) | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | |
CA2369070C (en) | 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof | |
FI93217C (en) | Process for the preparation of esters and amides of therapeutically active nucleoside derivatives | |
RU2372349C2 (en) | Method of producing rosuvastatin calcium salt (e) -7-[4-(4-fluorophehyl)-6-isopropyl-2-[methyl(methylsulphonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and crystalline intermediate products thereof | |
RU2210574C2 (en) | Purified steroid-sulfamate compounds, estrone-sulfamates | |
JPH06509082A (en) | Method for producing derivatives of baccatin 3 and 10-deacetylbaccatin 3 | |
PL316994A1 (en) | Method of bonding e, p- or l-selection to sialyl-lewis x or sialyl-lewis a | |
JPH05155898A (en) | Amidinophenylalanine derivative and preparation thereof | |
RU96117325A (en) | ANALOGUES Δ12,13 - ISOTAXOL, THEIR USE AS ANTITICAL CHARACTERISTICS AND THE CONTENT OF THEIR COMPOSITION | |
JP2006519869A5 (en) | ||
JP2006520822A5 (en) | ||
GB2025401A (en) | 5-fluoro ( uridine or 2 deoxy uridine derivatives | |
JP2813450B2 (en) | Method for producing 3- (L-pyroglutamyl) -L-thiazolidine-4-carboxylic acid and derivatives thereof | |
DE69012560T2 (en) | MACROLID FOR TREATING REVERSIBLE OBSTRUCTIVE VENTILATION DISEASES. | |
Prugh et al. | Methyl 3-0-benzyl-2, 4, 6-trideoxy-6-iodo-α-d-erythro-hexopyranoside, a chiral synthon for the synthesis of inhibitors of HMG-CoA reductase | |
HU217976B (en) | A method for separating 2-desoxi-2,2-difluorine-d-ribo furanosyle-alkyl-sulfonate anomers | |
CA1320951C (en) | Disaccharide derivatives | |
AU779412B2 (en) | 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use | |
ZA903343B (en) | Fluoro-amide derivatives | |
US3691181A (en) | Certain acyl derivatives of the antibiotic t-2636c | |
CA2010312C (en) | Peptide derivatives and their pharmaceutical use | |
US4962099A (en) | Chemical synthesis | |
KR920000694B1 (en) | Process for producing dipeptides derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20150303 |